Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role

International Journal of Cardiology

Volumn 206, Issue , 2016, Pages 71-76

  Seccia, Teresa Maria ^a   Caroccia, Brasilina ^a   Muiesan, Maria Lorenza ^b   Rossi, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Aldosterone; Angiotensin; Atrial fibrillation; Cardiovascular risk; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; APIXABAN; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONNECTIVE TISSUE GROWTH FACTOR; CONNEXIN 40; CONNEXIN 43; DABIGATRAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDOXABAN; LOSARTAN; RIVAROXABAN; SOTALOL; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CARDITIS; CELL JUNCTION; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; GENETIC VARIABILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEREDITY; HUMAN; HYPERTENSION; INCIDENCE; MUTATIONAL ANALYSIS; OXIDATIVE STRESS; POTASSIUM CURRENT; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; SINUS RHYTHM CONTROL; THROMBOEMBOLIC RISK; COMORBIDITY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEART ATRIUM REMODELING; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ATRIAL FIBRILLATION; ATRIAL REMODELING; COMORBIDITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84959327018     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.01.007     Document Type: Review

References (73)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
2. A.S. Go, E.M. Hylek, K.A. Phillips, and et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
3. S. Stewart, C.L. Hart, D.J. Hole, and J.J. McMurray Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study Heart 86 2001 516 521
4. Y. Miyasaka, M.E. Barnes, B.J. Gersh, and et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125
5. G.V. Naccarelli, H. Varker, J. Lin, and K.L. Schulman Increasing prevalence of atrial fibrillation and flutter in the United States Am. J. Cardiol. 104 2009 1534 1539
6. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
7. M.E. Hamer, J.A. Blumenthal, E.A. McCarthy, B.G. Phillips, and E.L. Pritchett Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia Am. J. Cardiol. 74 1994 826 829
8. P. Dorian, W. Jung, D. Newman, and et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy J. Am. Coll. Cardiol. 36 2000 1303 1309
9. T.J. Bunch, J.P. Weiss, B.G. Crandall, and et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia Heart Rhythm. 7 2010 433 437
10. W.S. Post, M.G. Larson, and D. Levy Hemodynamic predictors of incident hypertension The Framingham Heart Study Hypertension 24 1994 585 590
11. E. Phillips, and S.A. Levine Auricular fibrillation without other evidence of heart disease; a cause of reversible heart failure Am. J. Med. 7 1949 478 489
12. W.B. Kannel, P.A. Wolf, E.J. Benjamin, and D. Levy Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates Am. J. Cardiol. 82 1998 2N 9N
13. R.B. Schnabel, X. Yin, P. Gona, and et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study Lancet 386 2015 154 162
14. O.N.T.A.R.G.E.T. Investigators, S. Yusuf, K.K. Teo, and et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N. Engl. J. Med. 358 2008 1547 1559
15. P. Verdecchia, G. Reboldi, R. Gattobigio, and et al. Atrial fibrillation in hypertension: predictors and outcome Hypertension 41 2003 218 223
16. K. Wachtell, M. Lehto, E. Gerdts, and et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study J. Am. Coll. Cardiol. 45 2005 712 719
17. P.M. Okin, K. Wachtell, R.B. Devereux, and et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension JAMA 296 2006 1242 1248
18. P.M. Okin, D.A. Hille, A.C. Larstorp, and et al. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients Hypertension 66 2015 368 373
19. D. Conen, U.B. Tedrow, B.A. Koplan, R.J. Glynn, J.E. Buring, and C.M. Albert Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women Circulation 119 2009 2146 2152
20. I. Grundvold, P.T. Skretteberg, K. Liestol, and et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study Hypertension 59 2012 198 204
21. M. Domenech, A. Berruezo, I. Molina, L. Mont, and A. Coca Nighttime ambulatory blood pressure is associated with atrial remodelling and neurohormonal activation in patients with idiopathic atrial fibrillation Rev. Esp. Cardiol. (Engl. Ed.) 66 2013 458 463
22. A.J. Manolis, E.A. Rosei, A. Coca, and et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment Position Paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension J. Hypertens. 30 2012 239 252
23. D.G. Wyse, A.L. Waldo, J.P. DiMarco, and et al. A comparison of rate control and rhythm control in patients with atrial fibrillation N. Engl. J. Med. 347 2002 1825 1833
24. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trial N. Engl. J. Med. 363 2010 1875 1876
25. A. Ducharme, K. Swedberg, M.A. Pfeffer, and et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of Reduction in mortality and morbidity (CHARM) program Am. Heart J. 152 2006 86 92
26. S.H. Hohnloser, K.H. Kuck, and J. Lilienthal Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 2000 1789 1794
27. G. Opolski, A. Torbicki, D.A. Kosior, and et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Chest 126 2004 476 486
28. S. Mahida, S.A. Lubitz, M. Rienstra, D.J. Milan, and P.T. Ellinor Monogenic atrial fibrillation as pathophysiological paradigms Cardiovasc. Res. 89 2011 692 700
29. J.S. Healey, A. Baranchuk, E. Crystal, and et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis J. Am. Coll. Cardiol. 45 2005 1832 1839
30. Y.H. Chen, S.J. Xu, S. Bendahhou, and et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation Science 299 2003 251 254
31. D.C. Bartos, J.B. Anderson, R. Bastiaenen, and et al. A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation J. Cardiovasc. Electrophysiol. 24 2013 562 569
32. C.M. Campbell, J.D. Campbell, C.H. Thompson, and et al. Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation Circ. Arrhythm. Electrophysiol. 6 2013 960 966
33. L.S. Ravn, Y. Aizawa, G.D. Pollevick, and et al. Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation Heart Rhythm. 5 2008 427 435
34. Y. Yang, M. Xia, Q. Jin, and et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation Am. J. Hum. Genet. 75 2004 899 905
35. M. Xia, Q. Jin, S. Bendahhou, and et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation Biochem. Biophys. Res. Commun. 332 2005 1012 1019
36. T.M. Olson, A.E. Alekseev, X.K. Liu, and et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation Hum. Mol. Genet. 15 2006 2185 2191
37. T. Yang, P. Yang, D.M. Roden, and D. Darbar Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation Heart Rhythm. 7 2010 1246 1252
38. D. Darbar, P.J. Kannankeril, B.S. Donahue, and et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation Circulation 117 2008 1927 1935
39. P.T. Ellinor, E.G. Nam, M.A. Shea, D.J. Milan, J.N. Ruskin, and C.A. MacRae Cardiac sodium channel mutation in atrial fibrillation Heart Rhythm. 5 2008 99 105
40. M.G. Chelu, S. Sarma, S. Sood, and et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2 + leak promotes atrial fibrillation in mice J. Clin. Invest. 119 2009 1940 1951
41. J. Heijman, N. Voigt, S. Nattel, and D. Dobrev Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression Circ. Res. 114 2014 1483 1499
42. C.E. Chiang, L. Naditch-Brule, J. Murin, and et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry Circ. Arrhythm. Electrophysiol. 5 2012 632 639
43. H.M. van der Velden, M.J. van Kempen, M.C. Wijffels, and et al. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat J. Cardiovasc. Electrophysiol. 9 1998 596 607
44. S.M. Chaldoupi, S.S. Soedamah-Muthu, J. Regieli, and et al. Absence of connexin 40 gene polymorphism, as a marker of undetected atrial fibrillation in patients with unexplained cerebral ischemic events Eur. J. Cardiovasc. Prev. Rehabil. 16 2009 616 620
45. A.M. De Jong, A.H. Maass, S.U. Oberdorf-Maass, D.J. Van Veldhuisen, W.H. Van Gilst, and I.C. Van Gelder Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation Cardiovasc. Res. 89 2011 754 765
46. O. Adam, D. Lavall, K. Theobald, and et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation J. Am. Coll. Cardiol. 55 2010 469 480
47. K. Kaur, M. Zarzoso, D. Ponce-Balbuena, and et al. TGF-beta1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes PLoS One 8 2013 e55391
48. R.E. Schmieder, S.E. Kjeldsen, S. Julius, and et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial J. Hypertens. 26 2008 403 411
49. A. Goette, P. Hoffmanns, W. Enayati, U. Meltendorf, J.C. Geller, and H.U. Klein Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation Am. J. Cardiol. 88 2001 906 909 A8
50. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, and J.J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J. Am. Coll. Cardiol. 45 2005 1243 1248
51. G.P. Rossi, A. Sacchetto, E. Pavan, and et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma Circulation 95 1997 1471 1478
52. G.P. Rossi Cardiac consequences of aldosterone excess in human hypertension Am. J. Hypertens. 19 2006 10 12
53. D. Lavall, C. Selzer, P. Schuster, and et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation J. Biol. Chem. 289 2014 6656 6668
54. J. Zhao, J. Li, W. Li, and et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing Br. J. Pharmacol. 159 2010 1584 1594
55. J. Mant, D.A. Fitzmaurice, F.D. Hobbs, and et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial BMJ 335 2007 380
56. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation 130 2014 e199 e267
57. M. Proietti, A.M. Marra, E.J. Tassone, and et al. Frequency of left ventricular hypertrophy in non-valvular atrial fibrillation Am. J. Cardiol. 116 2015 877 882
58. R.G. Tieleman, Y. Plantinga, D. Rinkes, and et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation Europace 16 2014 1291 1295
59. B. Vaes, S. Stalpaert, K. Tavernier, and et al. The diagnostic accuracy of the MyDiagnostick to detect atrial fibrillation in primary care BMC Fam. Pract. 15 2014 (113-2296-15-113)
60. A.J. Camm, G.Y. Lip, R. De Caterina, and et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012 2719 2747
61. D. Roy, M. Talajic, S. Nattel, and et al. Rhythm control versus rate control for atrial fibrillation and heart failure N. Engl. J. Med. 358 2008 2667 2677
62. A.J. Camm, G. Breithardt, H. Crijns, and et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation) J. Am. Coll. Cardiol. 58 2011 493 501
63. F. Turnbull Blood pressure lowering treatment trialists' collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
64. G. Reboldi, G. Gentile, F. Angeli, G. Ambrosio, G. Mancia, and P. Verdecchia Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients J. Hypertens. 29 2011 1253 1269
65. L. Hansson, L.H. Lindholm, L. Niskanen, and et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
66. L. Hansson, L.H. Lindholm, T. Ekbom, and et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study Lancet 354 1999 1751 1756
67. G. Huang, J.B. Xu, J.X. Liu, and et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis Eur. J. Clin. Investig. 41 2011 719 733
68. M.P. Schneider, T.A. Hua, M. Bohm, K. Wachtell, S.E. Kjeldsen, and R.E. Schmieder Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis J. Am. Coll. Cardiol. 55 2010 2299 2307
69. K. Anand, A.N. Mooss, T.T. Hee, and S.M. Mohiuddin Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation Am. Heart J. 152 2006 217 222
70. O. Salehian, J. Healey, B. Stambler, and et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study Am. Heart J. 154 2007 448 453
71. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Y. S, T. K, and et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
72. R. Fogari, A. Mugellini, M. Destro, and et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients J. Cardiovasc. Pharmacol. 47 2006 46 50
73. R. Fogari, G. Derosa, I. Ferrari, and et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation Am. J. Hypertens. 21 2008 1034 1039